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Introduction
Type 2 diabetes mellitus (T2DM) is rising in incidence worldwide 
and constitutes a major public health burden (1). T2DM is charac-
terized by hyperglycemia and is caused by progressive peripheral 
insulin resistance and deficient insulin secretion from pancreatic β 
cells. Adipose tissue macrophages (ATMs) are considered crucial 
players that link obesity with insulin resistance and T2DM (2, 3). 
This is underscored by the fact that proinflammatory cytokines 
secreted from ATMs induce insulin resistance by a number of dif-
ferent mechanisms (4, 5). In line with these observations, several 
studies that target ATMs to attenuate the secretion of proinflam-
matory cytokines have shown beneficial effects with respect to 
insulin resistance (6, 7). Over the last years, several G protein–
coupled receptors (GPCRs) have emerged as critical regulators of 
ATM function (8–14), rendering them highly attractive as targets 
for drug development.
G protein–coupled bile acid receptor 1 (GPBAR1; also known 
as GPR131, and referred to herein as TGR5) is a bile acid–respon-
sive (BA-responsive) GPCR that, upon activation, triggers cAMP-
mediated downstream signaling. TGR5 is widely distributed and 
coordinates a large spectrum of biological processes, including 
bile homeostasis (15–19), gallbladder relaxation (20, 21), intestinal 
motility (22–24), and BA-induced itch and analgesia (25). Emerg-
ing evidence indicates that activation of the receptor confers 
protection against diet-induced diabesity via different cell-based 
mechanisms. TGR5 improves energy metabolism and glucose 
homeostasis via processes involving local thyroid hormone activa-
tion and glucagon-like peptide–1 (GLP-1) secretion (26, 27). The 
contribution of TGR5 in GLP-1–induced insulin secretion is fur-
ther underscored by the finding that BA sequestrants boost GLP-1 
secretion in a TGR5-dependent manner (28, 29). Enhanced TGR5 
signaling is also associated with reduced liver steatosis (26) and 
improved pancreatic β cell function (26, 30).
TGR5 is also expressed in cells of the hematopoietic system, 
such as monocytes and macrophages, and confers potent antiin-
flammatory properties in vitro and in vivo (31–36). Recent work 
from our laboratory revealed that the immune-suppressive actions 
of TGR5 in macrophages contribute to the prevention of the athero-
sclerotic process (34). Because chronic, low-grade inflammation is a 
hallmark not only of atherosclerosis, but also of obesity and T2DM, 
we speculated that the immune-regulatory functions of TGR5 may 
also affect some of the metabolic abnormalities acquired during the 
onset of obesity and obesity-induced insulin resistance.
In the current study, we investigated the properties of mac-
rophage TGR5 in the context of adipose tissue inflammation and 
associated diabesity. We found that Tgr5-deficient bone marrow 
chimeric mice (referred to herein as Tgr5bm–/– mice) and myeloid 
cell–specific Tgr5-knockout mice (LysM-Cre Tgr5fl/fl mice) with 
diet-induced obesity developed insulin resistance along with 
exacerbated inflammation in adipose tissue. Using these genet-
ic models, we demonstrated that deletion of TGR5 in macro-
phages was associated with increased chemokine expression 
and migration, which was partly caused by impaired activation 
of AKT–mTOR complex 1 (AKT-mTORC1) and translation of the 
liver inhibitory protein (LIP) isoform of the transcription factor 
CCAAT/enhancer binding protein β (C/EBPβ). The unanticipated 
link between TGR5 and the AKT-mTOR-LIP axis highlights a new 
mechanism in macrophages that contributes to the antidiabetic 
effects of TGR5 activators.
The bile acid–responsive G protein–coupled receptor TGR5 is involved in several metabolic processes, and recent studies 
suggest that TGR5 activation may promote pathways that are protective against diet-induced diabetes. Here, we investigated 
the role of macrophage-specific TGR5 signaling in protecting adipose tissue from inflammation and associated insulin 
resistance. Examination of adipose tissue from obese mice lacking macrophage Tgr5 revealed enhanced inflammation, 
increased chemokine expression, and higher macrophage numbers compared with control obese animals. Moreover, 
macrophage-specific deletion of Tgr5 exacerbated insulin resistance in obese animals. Conversely, pharmacological activation 
of TGR5 markedly decreased LPS-induced chemokine expression in primary macrophages. This reduction was mediated by 
AKT-dependent activation of mTOR complex 1, which in turn induced the differential translation of the dominant-negative 
C/EBPβ isoform, liver inhibitory protein (LIP). Overall, these studies reveal a signaling pathway downstream of TGR5 that 
modulates chemokine expression in response to high-fat diet and suggest that targeting this pathway has the potential to be 
therapeutically exploited for prevention of chronic inflammatory diseases and type 2 diabetes mellitus.
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of leukocyte TGR5 in glucose homeostasis and insulin responsive-
ness. We performed bone marrow transplantations to generate 
chimeric C57BL/6J mice carrying bone marrow of either Tgr5 WT 
or Tgr5-knockout mice (referred to herein as Tgr5bm+/+ and Tgr5bm–/– 
mice, respectively). Genotyping of the Tgr5 allele in circulating 
Results
Tgr5bm–/– mice display worsened high-fat diet–induced insulin resis-
tance. Earlier studies have shown that TGR5 protects against glu-
cose intolerance and insulin resistance induced by high-fat diet 
(HFD) (26). In the current study, we set out to determine the role 
Figure 1. Tgr5bm–/– mice display impaired insulin responsiveness. (A) Body weight curves of Tgr5bm+/+ and Tgr5bm–/– mice fed HFD for 18 weeks. n = 12 per 
group. (B) Body composition (fat and lean mass) of Tgr5bm+/+ and Tgr5bm–/– mice, determined by EchoMRI. n = 12 per group. (C) Left: Blood glucose levels during 
ITT (insulin; 0.5 U/kg) in Tgr5bm+/+ and Tgr5bm–/– mice fed HFD for 16 weeks. Right: Average area under the curve (AUC). n = 12 per group. (D) Left: Plasma insu-
lin levels during OGTT in Tgr5bm+/+ and Tgr5bm–/– mice fed HFD for 14 weeks. Right: Average AUC. n = 12 per group. (E) Left: Blood glucose levels during OGTT in 
Tgr5bm+/+ and Tgr5bm–/– mice fed HFD. Right: AUC. n = 12 per group. (F) HOMA-IR of HFD-fed Tgr5bm+/+ and Tgr5bm–/– mice. n = 12 per group. (G–I) Western blot of 
phospho-AKT (P-AKT, Ser473), total AKT, and HSP90 in (G) liver, (H) gastrocnemius muscle, and (I) eWAT of HFD-fed Tgr5bm+/+ and Tgr5bm–/– mice injected i.p. 
with vehicle or insulin (1 U/kg; 10 min). Quantitative densitometry of Western blots is also shown. n = 6 per group. Results represent mean ± SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001 vs. genotype; #P < 0.001 vs. control, 2-tailed Student’s t test or 1- or 2-way ANOVA with Bonferroni post-hoc analysis as appropriate.
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Tgr5bm+/+ mice (Figure 1F), pointing to increased insulin resistance 
in mice lacking leukocyte TGR5.
To further assess the role of leukocyte TGR5 in modulating 
insulin responsiveness, we determined insulin-stimulated AKT 
phosphorylation in a panel of insulin-responsive target tissues of 
Tgr5bm+/+ and Tgr5bm–/– mice fed HFD. While AKT phosphorylation 
was similarly induced by insulin in Tgr5bm+/+ and Tgr5bm–/– liver, a 
moderate decrease in AKT activation was observed in Tgr5bm–/– 
gastrocnemius muscle (Figure 1, G and H). However, insulin-stim-
ulated AKT phosphorylation was robustly decreased in the epidid-
ymal fat pads of Tgr5bm–/– versus Tgr5bm+/+ mice (Figure 1I). These 
data indicate that TGR5 deficiency in leukocytes predominantly 
reduces insulin responsiveness in adipose tissue.
Exacerbated adipose tissue inflammation in Tgr5bm–/– mice. 
Adipose tissue macrophages (ATMs) are a prominent source of 
inflammatory cytokines in obesity, which can directly trigger 
systemic insulin resistance (7, 37–39). Since the difference in 
insulin responsiveness in Tgr5bm–/– mice could not be attributed 
to quantitative changes in fat storage, we examined the extent of 
inflammation in adipose tissue. As expected, ATMs, which form 
crown-like structures (CLS) around adipocytes, were increased 
in HFD-fed Tgr5bm–/– mice compared with Tgr5bm+/+ controls (Fig-
leukocytes confirmed that the transplanted mice were chimeric 
(Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI76289DS1). Blood differentiation 
counts of transplanted mice did not reveal any significant effect 
caused by loss of function of TGR5 in leukocytes, except for a 
slight but not significant increase of red blood cell number in 
Tgr5bm–/– mice (Supplemental Table 1).
To evaluate the role of leukocyte TGR5 in regulating insulin 
resistance, mice were fed HFD for 18 weeks after recovery from 
transplantation. Contrary to the phenotype of global Tgr5–/– mice 
(26), body weight gain, as well as fat and lean mass, were similar 
between Tgr5bm+/+ and Tgr5bm–/– mice fed HFD (Figure 1, A and B). 
Food consumption and water intake were also comparable between 
the genotypes (Supplemental Figure 1, B and C). Despite the lack 
of difference in fat content, plasma glucose levels decreased more 
slowly during insulin tolerance test (ITT) in Tgr5bm–/– mice than in 
Tgr5bm+/+ littermates (Figure 1C). Plasma insulin concentrations 
of Tgr5bm–/– mice were significantly higher than those of Tgr5bm+/+ 
mice during oral glucose tolerance test (OGTT), whereas glucose 
clearance in Tgr5bm–/– mice was moderately impaired (Figure 1, D 
and E). In accordance, the calculated homeostasis model assess-
ment–insulin resistance (HOMA-IR) was higher in Tgr5bm–/– than in 
Figure 2. Exacerbated adipose tissue inflammation in Tgr5bm–/– mice. (A) Representative F4/80 staining of eWAT of HFD-fed Tgr5bm+/+ and Tgr5bm–/– 
mice. Arrows denote CLS. Scale bars: 50 μm. (B) Quantification of CLS from A (expressed as mean number per microscopic field). n = 3 per group. (C) 
mRNA levels of macrophage markers in eWAT of HFD-fed Tgr5bm+/+ and Tgr5bm–/– mice. n = 12 per group. (D–I) FACS analysis showing the percentage 
of (D) CD45+ leukocytes and (E) of CD11b+F4/80+Ly6G–Siglec-F– macrophages in the SVF of eWAT from HFD-fed Tgr5bm+/+ and Tgr5bm–/– mice. n = 8 per 
group. (F–I) Representative FACS analysis (F and H) and average mean intensity fluorescence (MIF, n = 8 per group; G and I) of (F and G) CD206 and 
(H and I) CD301 expression in CD11b+F4/80+Ly6G–Siglec-F– macrophages in eWAT of HFD-fed Tgr5bm+/+ and Tgr5bm–/– mice. (J and K) mRNA levels of (J) 
proinflammatory M1 and (K) antiinflammatory M2 markers in eWAT of HFD-fed Tgr5bm+/+ and Tgr5bm–/– mice. n = 12 per group. Results represent mean 
± SEM. *P < 0.05, **P < 0.01 vs. genotype, 2-tailed Student’s t test.
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significantly induced in the adipose tissue of Tgr5bm–/– mice 
(Figure 2C). Given the mild reduction in insulin sensitivity of 
Tgr5bm–/– muscle (Figure 1H), we also tested the expression of 
the macrophage marker genes in gastrocnemius derived from 
ure 2, A and B). In line with these data, mRNA expression levels 
of the macrophage marker genes EGF-like module containing, 
mucin-like, hormone receptor-like sequence 1 (Emr1; hereafter 
F4/80), Cd68, and integrin αM (Itgam; hereafter Cd11b) were 
Figure 3. LysM-Cre Tgr5fl/fl mice display impaired insulin responsiveness. (A) Body weight curves of Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice fed HFD for 12 
weeks. n = 12 per group. (B) Body composition (fat and lean mass) of Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice, determined by EchoMRI. n = 12 per group. (C) Left: 
Blood glucose levels during ITT (insulin; 0.75 U/kg) in Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice fed HFD for 10 weeks. Right: Average AUC. n = 12 per group. (D) 
Left: Plasma insulin levels during OGTT in Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice fed HFD for 8 weeks. Right: Average AUC. n = 12 per group. (E) Left: Blood 
glucose levels during OGTT in Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice fed HFD. Right: AUC. n = 12 per group. (F) HOMA-IR of HFD-fed Tgr5fl/fl and LysM-Cre Tgr5fl/fl  
mice. n = 12 per group. (G–I) Western blot of phospho-AKT (Ser473), total AKT, and HSP90 in (G) liver, (H) gastrocnemius muscle, and (I) eWAT of HFD-fed 
Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice injected i.p. with vehicle or insulin (1 U/kg; 10 min). Quantitative densitometry of Western blots is also shown. n = 6 
per group. Results represent mean ± SEM. *P < 0.05, **P < 0.01 vs. genotype; #P < 0.001 vs. control, 2-tailed Student’s t test or 1- or 2-way ANOVA with 
Bonferroni post-hoc analysis as appropriate.
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that leukocyte Tgr5 deficiency is associated with an increase of 
proinflammatory M1 ATMs upon HFD feeding.
LysM-Cre Tgr5fl/fl mice display increased HFD-induced insulin 
resistance. To confirm the contribution of macrophage TGR5 in 
the context of insulin resistance, we selectively deleted Tgr5 in 
macrophages by generating mice that express Cre under the con-
trol of the myeloid cell–specific M lysozyme promoter (referred to 
herein as LysM-Cre Tgr5fl/fl mice; Supplemental Figure 3A and ref. 
42). After 12 weeks of HFD feeding, LysM-Cre Tgr5fl/fl and control 
Tgr5fl/fl mice did not display any difference in body weight or com-
position (Figure 3, A and B). In agreement with the phenotype 
of the chimeric Tgr5bm–/– mice (Figure 1), ITT results in HFD-fed 
LysM-Cre Tgr5fl/fl mice were suggestive of increased insulin resis-
tance (Figure 3C). In further accord with our findings in Tgr5bm–/– 
mice, plasma insulin concentrations were significantly higher 
during OGTT, while glucose clearance was only moderately 
impaired (Figure 3, D and E). This resulted in a higher HOMA-IR 
in LysM-Cre Tgr5fl/fl mice (Figure 3F), indicative of worsened 
insulin resistance in mice lacking macrophage TGR5. The differ-
ence in insulin resistance was highly dependent on HFD feeding, 
since chow diet–fed LysM-Cre Tgr5fl/fl mice did not display any dif-
ference in ITT, insulin levels, or OGTT compared with controls 
(Supplemental Figure 3, B–D).
To further confirm the role of macrophage TGR5 in modu-
lating insulin responsiveness, we determined insulin-stimulated 
AKT phosphorylation in liver, muscle, and fat of HFD-fed Tgr5fl/fl 
and LysM-Cre Tgr5fl/fl mice. Whereas AKT phosphorylation was 
induced by insulin to a similar extent in Tgr5fl/fl and LysM-Cre Tgr5fl/fl 
liver, a slight decrease in AKT activation was observed in LysM-
Cre Tgr5fl/fl gastrocnemius (Figure 3, G and H). However, insulin-
stimulated AKT phosphorylation was significantly decreased in 
the epididymal white adipose tissue (eWAT) of LysM-Cre Tgr5fl/fl 
compared with Tgr5fl/fl mice (Figure 3I). These data indicate that 
Tgr5 deficiency in macrophages predominantly reduces insulin 
responsiveness in adipose tissue.
Tgr5bm–/– and Tgr5bm+/+ mice; however, no difference was found 
between the genotypes (Supplemental Figure 2A).
We then performed FACS analysis on stromal vascular frac-
tion (SVF) cells isolated from adipose tissue of Tgr5bm–/– and 
Tgr5bm+/+ mice. A trend toward higher leukocyte numbers (CD45+ 
cells) in the SVF of Tgr5bm–/– mice was observed (Figure 2D). In 
line with our previous findings, however, the number of ATMs, 
identified as F4/80+CD11b+Siglec-F–Ly6G– cells, was markedly 
increased in the adipose tissue of Tgr5bm–/– mice (Figure 2E). Given 
the primordial role of alternative M2 activation in the protection 
against insulin resistance (40, 41), we assessed M1/M2 polariza-
tion of ATMs by evaluating the expression of 2 established M2 
markers in macrophages, CD206 and CD301 (41). Expression 
of both was significantly reduced in macrophages isolated from 
Tgr5bm–/– mice (Figure 2, F–I).
To determine the underlying cause of the imbalance between 
M1 and M2 ATMs in Tgr5bm–/– mice, we next assessed the extent of 
inflammation in adipose tissue by analyzing several proinflammato-
ry (M1) and antiinflammatory (M2) genes (Figure 2, J and K). Expres-
sion of TNF-α (Tnfa), IL-1β (Il1b), and integrin αX (Itgax; hereafter 
Cd11c) was significantly increased in the adipose tissue of HFD-fed 
Tgr5bm–/– mice, whereas IL-6 (Il6), nitric oxide synthase 2, inducible 
(Nos2; hereafter iNos), and IL-12B (Il12b; also known as Il12) were 
unchanged or showed only a trend toward increase (Figure 2J).
Consistent with the FACS analysis of CD206 and CD301 
(Figure 2, F–I), gene expression of M2 markers, such as IL-10 
(Il10), C-type lectin domain family 10, member A (Clec10a; here-
after Mgl1), chitinase 3-like 3 (Chi3l3; hereafter Ym1) and resistin-
like α (Retnla; also known as Fizz1) was significantly attenuated 
in adipose tissue of Tgr5bm–/– mice, whereas arginase 1 (Arg1), an 
M2 signature gene, was not changed (Figure 2K). In contrast to 
our findings in adipose tissue, M1 and M2 markers were not dif-
ferentially expressed in gastrocnemius derived from Tgr5bm–/– and 
Tgr5bm+/+ mice, except for a slight increase in Il6 mRNA (Supple-
mental Figure 2, B and C). Taken together, these results indicate 
Figure 4. Exacerbated adipose tissue inflammation in LysM-Cre Tgr5fl/fl mice. (A) Representative F4/80 staining of eWAT of HFD-fed Tgr5fl/fl and LysM-
Cre Tgr5fl/fl mice. Arrows indicate CLS. Scale bars: 50 μm. (B) Quantification of CLS from A (expressed as mean per microscopic field). n = 3 per group. (C) 
mRNA levels of macrophage markers in eWAT of HFD-fed Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice. n = 12 per group. (D and E) mRNA levels of (D) proinflamma-
tory M1 and (E) antiinflammatory M2 markers in eWAT of HFD-fed Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice. n = 12 per group. Results represent mean ± SEM.  
*P < 0.05, **P < 0.01 vs. genotype, 2-tailed Student’s t test.
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Exacerbated adipose tissue inflammation in LysM-Cre Tgr5fl/fl 
mice. Like the chimeric Tgr5bm–/– mice, LysM-Cre Tgr5fl/fl mice also 
displayed more ATMs than their HFD-fed control littermates, as 
implied by the increased incidence of CLS (Figure 4, A and B). In 
line with these data, mRNA expression levels of the macrophage 
marker genes F4/80, Cd68, and Cd11b were significantly induced 
in adipose tissue of LysM-Cre Tgr5fl/fl mice fed HFD, but not chow 
diet (Figure 4C and Supplemental Figure 3E).
To assess whether the imbalance between M1 and M2 ATMs 
was also present in LysM-Cre Tgr5fl/fl eWAT, we analyzed the extent 
of inflammation in this tissue. Expression of the M1 markers Tnfa, 
Cd11c, Il1b, Il6, and Il12b was significantly increased in eWAT of 
LysM-Cre Tgr5fl/fl mice fed HFD, whereas iNos only showed a trend 
toward increase (Figure 4D). On the other hand, gene expression 
of M2 markers, such as Il10 and Mgl1, was significantly attenuated 
in LysM-Cre Tgr5fl/fl eWAT, while Arg1, Ym1, and Retnla trended 
toward a decrease (Figure 4E). Taken together, these results indi-
cate that macrophage TGR5 deficiency is characterized by an 
increase of proinflammatory M1 ATMs upon HFD feeding.
TGR5 activation does not affect M2 polarization. Next, we 
investigated whether TGR5 directly renders macrophages more 
susceptible for M2 polarization in vitro. We generated bone mar-
row–derived primary macrophages (BMDMs) and exposed the 
differentiated cells to the TGR5 agonist 6α-ethyl-23(S)-methyl-
cholic acid (S-EMCA; hereafter INT-777) (26, 43, 44) and/or to 
IL-4, a Th2 cytokine well known to promote differentiation of 
alternative M2 macrophages (45–47). As expected, IL-4 treat-
ment induced M2 polarization; however, stimulation of BMDMs 
with INT-777, alone or together with IL-4, did not increase the 
expression of the M2 antiinflammatory genes Arg1, Il10, Ym1, 
Mgl1, and Retnla (Figure 5, A–E). In addition, Tgr5 transcript 
levels were not changed in BMDMs upon M1 or M2 polarization 
with LPS or IL-4, respectively (Figure 5F). These data indicate 
that activation of TGR5 in macrophages does not promote dif-
ferentiation toward the M2 phenotype.
TGR5 deletion induces chemokine-mediated macrophage infiltra-
tion. The chemokine signaling network is also crucial in ATM func-
tion (48). We therefore analyzed the expression of several chemo-
kines and chemokine receptors in adipose tissue of Tgr5bm–/– mice, 
LysM-Cre Tgr5fl/fl mice, and their respective controls. Expression 
of the ligand Ccl2 was significantly increased in eWAT of HFD-fed 
Tgr5bm–/– and LysM-Cre Tgr5fl/fl mice compared with controls, while 
the receptor, Ccr2, and its other ligand, Ccl7, trended toward an 
increase (Figure 6, A and C). Furthermore, expression of the che-
mokine receptor Ccr5 and its ligands Ccl3 and Ccl4 was robustly 
induced in adipose tissue derived from Tgr5bm–/– and LysM-Cre 
Tgr5fl/fl mice compared with controls (Figure 6, B and D). Given the 
increase in chemokine and chemokine receptors in vivo, we next 
examined the effect of TGR5 on the migration of primary mac-
rophages in vitro. In this experiment, we stimulated TGR5 with 
INT-777 to ensure strong TGR5 activation in the potential absence 
of endogenous ligands. INT-777 reduced the ability of Tgr5+/+ 
primary macrophages to migrate in vitro toward CCL2, an effect 
that was not observed in Tgr5–/– primary macrophages (Figure 6E). 
More importantly, the absence of TGR5 significantly increased 
the number of macrophages able to invade an implanted Matrigel 
plug in vivo (Figure 6F). Taken together, these data indicate that 
TGR5 deficiency is associated with enhanced chemokine expres-
sion that could mediate obesity-induced macrophage recruitment 
and activation in adipose tissue.
We then investigated whether TGR5 activation can directly 
regulate chemokine expression in vitro. Stimulation of Tgr5+/+ 
and Tgr5–/– BMDMs with LPS induced similar expression levels of 
multiple chemokine genes, including Ccl2, Ccl3, Ccl4, Ccl5, Ccl7, 
Figure 5. TGR5 is dispensable for IL-4–induced M2 ATM polarization in vitro. (A–E) mRNA levels of M2 genes (A) Arg1, (B) Il10, (C) Ym1, (D) Mgl1, and (E) 
Retnla in primary BMDMs isolated from Tgr5+/+ or Tgr5–/– mice. BMDMs were stimulated with IL-4 (100 ng/ml) for 24 hours in the absence or presence of 
the TGR5 agonist INT-777 (30 μM). n = 6 per condition. (F) mRNA levels of Tgr5 in primary BMDMs isolated from Tgr5+/+ or Tgr5–/– mice and stimulated with 
IL-4 (100 ng/ml) or LPS (10 ng/ml) for 24 hours. n = 6 per condition. Results represent mean ± SEM. ***P < 0.001 vs. genotype; #P < 0.001 vs. control, 1-way 
ANOVA with Bonferroni post-hoc analysis.
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Ccl8, and Ccr5 (Figure 6, G–I, and Supplemental Figure 4, A–E). 
INT-777–mediated TGR5 activation significantly attenuated the 
LPS-dependent increase of Ccl2, Ccl3, and Ccl4 expression in 
Tgr5+/+ BMDMs, but not Tgr5–/– BMDMs (Figure 6, G–I), without 
affecting other chemokines and chemokine receptors (Supple-
mental Figure 4, A–E), indicative of a selective effect of TGR5 on 
a particular set of chemokines.
TGR5 activation reduces chemokine expression through the AKT-
mTOR-LIP axis. Chemokine production is regulated by several 
transcription factors and nuclear receptors (49, 50). We therefore 
investigated whether TGR5 modulation could regulate chemokine 
expression through one of these factors. Neither the absence of 
TGR5 nor its activation affected the expression of PPARγ (Pparg1), 
liver X receptor α (Lxra), liver X receptor β (Lxrb), or their target 
genes (Supplemental Figure 5, A–I). We previously demonstrated 
that TGR5 stimulation inhibits NF-κB activity and has no effect on 
the proinflammatory component of the AP-1 complex, c-Jun (34). In 
order to identify other mechanisms, we explored the role of C/EBPβ, 
another established regulator of chemokine expression (51). The 3 
C/EBPβ isoforms — full liver activating protein (LAP*), liver activat-
ing protein (LAP), and LIP — are translated from a single intron-less 
gene (52). The smallest C/EBPβ isoform, LIP, lacks the N-terminal 
transactivation domain and acts as a dominant-negative regulator 
of the LAP isoform of C/EBPβ or of other interacting transcription 
Figure 6. Loss of TGR5 induces chemokine expression and macrophage migration. (A and B) mRNA levels of chemokines and their cognate receptors in 
eWAT of HFD-fed Tgr5bm+/+ and Tgr5bm–/– mice. n = 12 per group. (C and D) mRNA levels of chemokines and their cognate receptors in eWAT of HFD-fed Tgr5fl/fl  
and LysM-Cre Tgr5fl/fl mice. n = 12 per group. (E) Migration of primary macrophages isolated from Tgr5+/+ or Tgr5–/– mice in a Transwell migration assay in 
response to CCL2 (100 ng/ml) in the presence or absence of INT-777 (30 μM). n = 3 per group. (F) Macrophage invasion into Matrigel plugs in Tgr5+/+ and Tgr5–/– 
mice. Left: Quantification of macrophages that invaded the Matrigel plugs. n = 3 per group. Right: Representative MAC3 staining to detect macrophages. 
Original magnification, ×20. (G–I) mRNA levels of chemokines (G) Ccl2, (H) Ccl3, and (I) Ccl4 in primary BMDMs isolated from Tgr5+/+ or Tgr5–/– mice and then 
stimulated with LPS (10 ng/ml) for 24 hours, in the presence or absence of INT-777 (30 μM). n = 6 per group. Results represent mean ± SEM. *P < 0.05,  
**P < 0.01, ***P < 0.001 vs. genotype; #P < 0.001 vs. control, 2-tailed Student’s t test or 1-way ANOVA with Bonferroni post-hoc analysis as appropriate.
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Control of LIP expression is mediated by differential ini-
tiation of protein translation through the activity of eukaryotic 
translation initiation factors (eIFs) (54). Previous studies have 
shown that mTOR enhances the level of accessible eIF-4E (57), 
thereby increasing the expression of the truncated C/EBPβ iso-
form LIP in an upstream ORF–dependent (uORF-dependent) 
manner (54). In light of this mechanism, we sought to determine 
whether TGR5-dependent activation of the mTOR pathway 
could be responsible for the increase in LIP in our model. Stimu-
factors (52–55). We first investigated whether TGR5 could regulate 
C/EBPβ expression. In accordance with the proinflammatory role of 
C/EBPβ (56), stimulation of primary macrophages with LPS induced 
C/EBPβ expression, at both the mRNA and the protein level (Fig-
ure 7, A–C). Notably, activation of TGR5 by INT-777 in LPS-treated 
BMDMs did not affect the levels of Cebpb mRNA, but reversed the 
ratio of C/EBPβ isoforms, marked by an increase in LIP protein (Fig-
ure 7, A–C). These data indicate that TGR5 can inhibit the proinflam-
matory LAP transcription factor by inducing LIP expression (52).
Figure 7. TGR5 activation in macrophages increases the expression of the C/EBPβ-inhibitory isoform LIP. (A) mRNA levels of Cebpb in primary BMDMs 
isolated from Tgr5+/+ or Tgr5–/– mice and stimulated with LPS (10 ng/ml) in the presence or absence of INT-777 (30 μM). n = 6 per condition. (B) Western blot 
of C/EBPβ isoforms (LAP and LIP) and HSP90 in primary BMDMs isolated from Tgr5+/+ or Tgr5–/– mice and stimulated with LPS (10 ng/ml) for 8 hours in the 
presence or absence of INT-777 (30 μM). (C) LIP/LAP ratio, calculated by densitometry of Western blots in B. n = 6 per group. (D) Western blot of the AKT-
mTOR signaling pathway in primary BMDMs isolated from Tgr5+/+ or Tgr5–/– mice and stimulated with LPS (10 ng/ml) for 8 hours in the presence or absence 
of INT-777 (30 μM). (E–H) Quantitative densitometry of Western blots in D. n = 6 per group. Results represent mean ± SEM. *P < 0.05, **P < 0.01,  
***P < 0.001 vs. genotype; #P < 0.001 vs. control, 1-way ANOVA with Bonferroni post-hoc analysis.
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modulates chemokine expression via a mechanism involving 
AKT-mTOR–dependent induction of LIP expression.
Discussion
Here, we showed that specific deletion of TGR5 in mouse mac-
rophages exacerbates HFD-induced insulin resistance without 
affecting body weight and adipose mass. We found that adipose 
tissue of Tgr5bm–/– and LysM-Cre Tgr5fl/fl mice is characterized by 
increased infiltration of proinflammatory M1 ATMs and enhanced 
expression of chemokines. Furthermore, we demonstrated that 
TGR5 activation reduces chemokine expression in macrophages 
via mTOR-dependent upregulation of the C/EBPβ isoform LIP 
and decreases ATM infiltration, thereby ameliorating obesity-
induced insulin resistance.
Several lines of evidence point to an important role of ATMs in 
the development of systemic insulin resistance and glucose intoler-
ance and in the progression of the metabolic syndrome (5, 39, 63). In 
the setting of obesity, proinflammatory cytokines and chemokines, 
lation of BMDMs with LPS induced the AKT-mTOR pathway to 
a similar extent in both Tgr5+/+ and Tgr5–/– cells (Figure 7, D–H). 
Interestingly, coexposure of LPS and INT-777 further increased 
the phosphorylation of AKT, mTOR, and p70S6K — and, more 
importantly, induced the hyperphosphorylation of 4E-BP — in 
Tgr5+/+ BMDMs, but not Tgr5–/– BMDMs (Figure 7, D–H). Inhibi-
tion of mTORC1 with rapamycin blocked the INT-777–mediated 
increase in LIP translation (Figure 8, A and B), which indicates 
that TGR5 stimulation increases LIP protein levels in a mTOR-
dependent manner.
C/EBPβ binding sites have been identified in the promoter 
regions of multiple proinflammatory genes, including Ccl2 (58–
60), Ccl3, and Ccl4 (61, 62). Accordingly, inhibition of mTORC1 
with rapamycin reversed the INT-777–mediated decrease of 
Ccl2, Ccl3, and Ccl4 expression in Tgr5+/+ BMDMs, but not Tgr5–/– 
BMDMs (Figure 8, C–E), which indicates that reduction of che-
mokines by TGR5 activation is critically dependent on mTOR 
signaling. Taken together, these results demonstrate that TGR5 
Figure 8. TGR5 activation in macrophages reduces chemokine gene expression in a mTOR-dependent manner. (A) Western blot of C/EBPβ isoforms (LAP 
and LIP) and HSP90 in primary BMDMs isolated from Tgr5+/+ or Tgr5–/– mice and stimulated with LPS (10 ng/ml) for 8 hours in the presence or absence of 
INT-777 (30 μM) and the mTORC1 inhibitor rapamycin (10 nM). (B) LIP/LAP ratio, calculated by densitometry of Western blots in A. n = 6 per condition. 
(C–E) mRNA levels of chemokines (C) Ccl2, (D) Ccl3, and (E) Ccl4 in primary BMDMs isolated from Tgr5+/+ or Tgr5–/– mice and stimulated with LPS (10 ng/ml) 
for 8 hours in the presence or absence of INT-777 (30 M) and rapamycin (10 nM). n = 6 per group. Results represent mean ± SEM. *P < 0.05, **P < 0.01 vs. 
genotype; #P < 0.001 vs. control, 1-way ANOVA with Bonferroni post-hoc analysis.
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contribute to the glucose-lowering actions of TGR5 (88), including 
stimulation of energy expenditure (27), secretion of the incretin 
GLP-1 (26, 28, 29, 89) and direct stimulation of insulin secretion 
from isolated pancreatic islets (30). Our present findings dem-
onstrated that TGR5 activation can alter ATM function, thereby 
improving insulin action. These data indicate that the role of TGR5 
in glucose homeostasis involves multiple tissues and processes.
In conclusion, we have elucidated a novel multicomponent 
TGR5-AKT-mTOR signaling pathway that induces differential 
translation of the C/EBPβ isoform LIP in macrophages. This axis 
links TGR5 tightly with obesity-induced insulin resistance through 
modulation of chemokine expression and ATM function. TGR5 
activation in macrophages may hence be a promising approach to 
prevent insulin resistance and treat T2DM and associated inflam-
matory and metabolic disorders.
Methods
Animals. Mice were housed with ad libitum access to water and food 
and kept under a 12-hour dark/12-hour light cycle. The whole-body 
Tgr5–/– mouse model has been described previously (26). Tgr5fl/fl mice 
were crossed with Lysozyme M–Cre mice (Jackson Laboratories) and 
then further intercrossed to generate macrophage-specific Tgr5 knock-
out (LysM-Cre Tgr5fl/fl) and control Tgr5fl/fl mice on a pure C57BL/6J 
background. 8-week-old mice were fed either chow diet or HFD 
(D12492; Research Diet) for 12 weeks. To generate bone marrow chi-
meras, 10-week-old male C57BL/6J recipient mice were subjected to 
2 exposures of total body X irradiation of 4.25 Gy (RS2000 Irradiator; 
Rad Source), after NK cell depletion by monoclonal PK136 antibody 
injection. Tgr5+/+ or Tgr5–/– littermates aged 4–6 weeks were used as 
bone marrow donors. After 4 weeks of recovery, which included treat-
ment with Baytril (Bayer) and Dafalgan (Bristol-Myers Squibb), the 
Tgr5bm+/+ and Tgr5bm–/– mice were fed HFD (D12492; Research Diet), 
then sacrificed 18 weeks after initiation of diet. Tgr5 deletion in the leu-
kocytes was confirmed using the primers 5′-AGAGCCAAGAGGGA-
CAATCC-3′ and 5′-TGGGTGAGTGGAGTCTTCCT-3′.
Mouse phenotyping. Mouse body weight was assessed weekly. 
Food and water intake were measured manually over a 24-hour peri-
od. Body composition was analyzed by noninvasive monitoring of fat 
and lean masses using EchoMRI (Echo Medical Systems), as previ-
ously described (90).
ITT was performed by measuring blood glucose following i.p. 
injection of insulin (0.5–0.75 U/kg) after a 5-hour fast. Blood glucose 
was determined by ACCU-CHEK glucose meters (Roche).
OGTT was performed by measuring blood glucose following oral 
administration of glucose (2 g/kg) after overnight fasting. Blood glu-
cose was determined by ACCU-CHEK glucose meters (Roche), and 
plasma insulin levels were measured by specific ELISA kits (Crystal 
Chem), following the manufacturer’s instructions.
To assess changes in insulin sensitivity, HOMA-IR (91) was calcu-
lated as (fasting plasma glucose × fasting serum insulin)/58.32.
Western blotting. For insulin-stimulated phospho-AKT analysis, 
mice were fasted overnight, and liver, gastrocnemius, and eWAT were 
collected 10 minutes after i.p. injection of insulin (1 U/kg) and snap 
frozen in liquid nitrogen.
Tissues and cells were lysed using RIPA buffer (50 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 
2 mM EDTA, and 50 mM NaF) supplemented with 1 mM PMSF and pro-
markers of M1 macrophages, recruit additional macrophages to the 
adipose tissue, thus reinforcing tissue inflammation and insulin 
resistance via a multitude of mechanisms (37, 64–66). Knockout 
mouse studies have shown that CCR2 and its ligand CCL2 are pivot-
al in triggering obesity-induced insulin resistance and are required 
for accumulation of inflammatory macrophages in fat (67–70). 
CCL2 was also shown to increase macrophage content via ATM pro-
liferation, in addition to its effect on blood monocyte recruitment 
(71). We observed that Ccl2 expression, together with that of other 
chemokines and their receptors, was increased in the fat of HFD-fed 
mice lacking macrophage TGR5. This could be partially explained 
by the higher macrophage number in this tissue, together with a 
direct effect of TGR5 activation on Ccl2, Ccl3, and Ccl4 in primary 
macrophages. We therefore propose that the reduced expression of 
Ccl2, Ccl3, and Ccl4 subsequent to TGR5 activation attenuates ATM 
accumulation and enhances insulin sensitivity.
Our finding of impaired induction of the negative C/EBPβ 
isoform LIP provides an explanation for the elevated chemokine 
expression in Tgr5–/– macrophages and Tgr5bm–/– and LysM-Cre 
Tgr5fl/fl adipose tissue. We demonstrated that the TGR5-medi-
ated selective increase in LIP was achieved through alternative 
translation triggered by enhanced AKT-mTOR signaling. Indeed, 
mTOR signaling affects the activity of the translation initiation 
factor eIF-4E, which is involved in C/EBPβ isoform switching 
(54, 72). Inhibition of mTOR/mTORC1 by rapamycin shifted 
the C/EBPβ isoform ratio in favor of LAP. The importance of 
this mTOR-dependent switch in C/EBPβ isoform translation has 
been previously demonstrated in osteoblast and osteoclast dif-
ferentiation (73, 74), bone formation (75), cancer progression (53, 
76, 77), liver regeneration (78), and inflammation (79). Although 
C/EBPβ-null mice have been generated to address the function 
of C/EBPβ in vivo (80), those mice lack both LIP and LAP iso-
forms, and are hence not appropriate to dissect the specific func-
tion of each isoform. Selective deletion of the dominant-negative 
isoform LIP has been achieved by generating a mouse line defi-
cient for the C/EBPβ uORF initiation codon that fails to initiate 
LIP translation (C/EBPβΔuORF mice) (81). In this mouse line, lack 
of LIP expression exacerbates the induction of C/EBPβ target 
genes in a model of partial hepatectomy–induced inflammation. 
Together, these results suggest that TGR5-mediated LIP induc-
tion contributes to the suppression of inflammatory markers that 
are normally boosted by other transcription factors, including the 
LAP isoform of C/EBPβ. As the b-ZIP domain of LAP has been 
reported to interact with the Rel homology domain of NF-κB and 
to enhance NF-κB–dependent transcription (82–85), the domi-
nant-negative C/EBPβ isoform LIP could also blunt NF-κB acti-
vation and further decrease the inflammatory response. Several 
studies demonstrate that TGR5 activation inhibits NF-κB signal-
ing through pleiotropic mechanisms, including IκBα, CREB, and 
c-Fos phosphorylation (32, 34, 36). Our present data add modula-
tion of LIP translation to the means by which TGR5 could reduce 
the inflammatory actions of NF-κB.
Based on our findings, we propose that macrophage TGR5 con-
tributes to the systemic insulin-sensitizing effects of BAs. BAs are 
well-characterized endogenous TGR5 ligands (44) that are robustly 
induced in human plasma after a glucose challenge (86) and corre-
late with enhanced insulin sensitivity (26, 87). Several mechanisms 
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herent cells were collected, seeded at 105 cells/ml in bacteriological 
plates, and grown for 7 days. Differentiated BMDMs were stimulated 
with LPS (10 ng/ml) or with IL-4 (100 ng/ml) for 8–24 hours in the 
presence or absence of the TGR5 agonist INT-777 (30 μM) and/or the 
mTOR inhibitor rapamycin (10 nM; Sigma-Aldrich).
In vitro chemotaxis assay. Primary macrophages (200,000 cells/
well), pretreated with 30 μM INT-777 for 24 hours, were loaded into 
the upper portion of a 6.5-mm Transwell with 8.0-μm Pore Polycar-
bonate Membrane Insert (Corning); DMEM with CCL2 (100 ng/ml) 
was placed in the lower chamber. After 6 hours of migration, cells were 
fixed in Shandon Formal Fixx (Thermo Scientific). Cells were then 
stained with DAPI and counted.
Matrigel plug assay. In total, 700 μl growth factor–reduced Matrigel, 
with 200 ng/ml basic fibroblast growth factor (Invitrogen) and 60 U/ml 
heparin (Sigma-Aldrich) added, was injected s.c. into Tgr5+/+ and Tgr5–/– 
mice. After 7 days, the Matrigel plug was removed, fixed in Shandon 
Formal Fixx (Thermo Scientific), and processed for immunohisto-
chemistry using a MAC3 antibody (BD Biosciences — Pharmingen).
Statistics. Prism software (GraphPad) was used for statistical analy-
sis. All results were expressed as mean ± SEM. P values were calculated 
by 2-tailed Student’s t test or 1- or 2-way ANOVA with Bonferroni post-
hoc analysis as appropriate. For analysis between genotypes, a P value 
less than 0.05 was considered significant; for analysis compared with 
control, P values less than 0.001 (extremely significant) are indicated.
Study approval. All animal experiments were carried out accord-
ing to national Swiss and EU ethical guidelines and were approved by 
the local animal experimentation committee of the Canton de Vaud 
(license no. 2614).
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tease and phosphatase inhibitor cocktails (Roche). Lysates were incu-
bated on ice and cleared by centrifugation at 18,500 g for 15 minutes 
at 4°C. Protein concentration was determined by the Lowry method, 
and samples were analyzed for immunoblotting using standard pro-
cedures. Antibodies against phospho-AKT (Ser473) (Cell Signaling), 
AKT (Cell Signaling), phospho-mTOR (Ser2448) (Cell Signaling), 
mTOR (Cell Signaling), phospho-p70S6K (Thr389) (Cell Signaling), 
p70S6K (Cell Signaling), phospho-4E-BP1 (Thr37/46) (Cell Signal-
ing), 4E-BP1 (Cell Signaling), C/EBPβ (Santa Cruz Biotechnology), 
and HSP90 (BD Biosciences) were used for Western blot analysis.
Histology and immunostaining. H&E staining was performed as 
described previously (92). Antibodies against F4/80 (Abcam) were 
used for immunohistochemistry to detect macrophages. F4/80 stain-
ing was visualized using HRP-conjugated goat anti-rat IgG antibodies 
(Jackson) and DAB substrate (Sigma-Aldrich). Microphotographs were 
taken on wide-field microscopes (Olympus) with a CCD camera. Aver-
age adipocyte size was quantified by measuring a total of 150 adipo-
cytes in the eWAT using ImageJ.
qRT-PCR. RNA was isolated from tissues and cells using TRI 
Reagent (Ambion), after which cDNA was synthesized (Qiagen). Real-
time qRT-PCR was performed using SYBR green (Roche) in the Light-
cycler 480 II (Roche). All mRNA expression levels were corrected for 
expression of the housekeeping gene 36B4 or β2-microglobulin.
FACS analysis. Epididymal fat pads were weighed, rinsed in phos-
phate-buffered saline and minced in HBSS. Tissue suspensions were treat-
ed with collagenase (Sigma-Aldrich) at a final concentration of 1 mg/ml 
for 80 minutes at 37°C with shaking. The cell suspensions were filtered 
through a 70-μm filter and centrifuged at 300 g for 5 minutes. Stromal 
vascular cells were incubated in staining buffer (HBSS plus 25 mM 
HEPES) containing antibodies to block the Fc receptor (Fc γ RIIb/CD16-2; 
derived from hybridoma 2.4G2) and stained with a combination of the 
following antibodies: PE-Cy5.5–labeled CD45 (EBioscience), FITC-
labeled Ly6G (MACS), BV421-labeled Siglec-F (BD Horizon), PE-Cy7–
labeled CD11b (EBioscience), PE-labeled CD301 (BioLegend), PE-
labeled CD206 (Biolegend), APC-labeled F4/80 (Ebioscience). FACS 
analysis was performed on a Cyan analyzer (Beckman Coulter), and 
FlowJo software was used for data analysis.
Derivation of macrophages and stimulation. BMDMs were isolated 
from the femurs and tibias of sibling 8- to 10-week-old Tgr5+/+ and 
Tgr5–/– mice. Cells were plated on bacteriological plastic plates in mac-
rophage growth medium consisting of RPMI-1640 (Invitrogen), 1 mM 
sodium pyruvate (Invitrogen), 1× nonessential amino acids (Invitro-
gen), 5 mM penicillin/streptomycin (Invitrogen), and 10% heat-inac-
tivated fetal bovine serum (GE Healthcare) supplemented with 10% 
L-cell-conditioned medium as a source of CSF-1. After 1 day, nonad-
 1. Nolan CJ, Damm P, Prentki M. Type 2 diabe-
tes across generations: from pathophysiol-
ogy to prevention and management. Lancet. 
2011;378(9786):169–181.
 2. Aouadi M, et al. Gene silencing in adipose tissue 
macrophages regulates whole-body metabo-
lism in obese mice. Proc Natl Acad Sci U S A. 
2013;110(20):8278–8283.
 3. Weisberg SP, et al. Obesity is associated with 
macrophage accumulation in adipose tissue.  
J Clin Invest. 2003;112(12):1796–1808.
 4. Odegaard JI, Chawla A. Pleiotropic actions of 
insulin resistance and inflammation in metabolic 
homeostasis. Science. 2013;339(6116):172–177.
 5. Olefsky JM, Glass CK. Macrophages, inflamma-
tion, and insulin resistance. Annu Rev Physiol. 
2010;72:219–246.
 6. Johnson AM, Olefsky JM. The origins and drivers 
of insulin resistance. Cell. 2013;152(4):673–684.
 7. Osborn O, Olefsky JM. The cellular and signaling 
networks linking the immune system and metab-
olism in disease. Nat Med. 2012;18(3):363–374.
 8. Kennedy A, Webb CD, Hill AA, Gruen ML, Jackson 
LG, Hasty AH. Loss of CCR5 results in glucose 
intolerance in diet-induced obese mice. Am J 
Physiol Endocrinol Metab. 2013;305(7):E897–E906.
 9. Lim J, et al. C5aR and C3aR antagonists each 
inhibit diet-induced obesity, metabolic dysfunc-
tion, and adipocyte and macrophage signaling. 
FASEB J. 2013;27(2):822–831.
 10. Macia L, et al. Neuropeptide y1 receptor in 
immune cells regulates inflammation and insulin 
resistance associated with diet-induced obesity. 
Diabetes. 2012;61(12):3228–3238.
 11. Oh DY, et al. GPR120 is an omega-3 fatty 
acid receptor mediating potent anti-inflam-
Downloaded from http://www.jci.org on January 11, 2016.   http://dx.doi.org/10.1172/JCI76289
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
5 4 3 5jci.org   Volume 124   Number 12   December 2014
matory and insulin-sensitizing effects. Cell. 
2010;142(5):687–698.
 12. Osborn O, et al. G protein-coupled recep-
tor 21 deletion improves insulin sensitiv-
ity in diet-induced obese mice. J Clin Invest. 
2012;122(7):2444–2453.
 13. Phieler J, et al. The complement anaphylatoxin 
C5a receptor contributes to obese adipose tissue 
inflammation and insulin resistance. J Immunol. 
2013;191(8):4367–4374.
 14. Poursharifi P, et al. C5L2 and C5aR interaction in 
adipocytes and macrophages: insights into adi-
poimmunology. Cell Signal. 2013;25(4):910–918.
 15. Hov JR, et al. Mutational characterization of the 
bile acid receptor TGR5 in primary sclerosing 
cholangitis. PLoS One. 2010;5(8):e12403.
 16. Keitel V, Cupisti K, Ullmer C, Knoefel WT, 
Kubitz R, Haussinger D. The membrane-bound 
bile acid receptor TGR5 is localized in the epi-
thelium of human gallbladders. Hepatology. 
2009;50(3):861–870.
 17. Masyuk AI, et al. Ciliary subcellular localization 
of TGR5 determines the cholangiocyte functional 
response to bile acid signaling. Am J Physiol Gastro-
intest Liver Physiol. 2013;304(11):G1013–G1024.
 18. Pean N, et al. The receptor TGR5 protects the 
liver from bile acid overload during liver regener-
ation in mice. Hepatology. 2013;58(4):1451–1460.
 19. Vassileva G, et al. Targeted deletion of Gpbar1 
protects mice from cholesterol gallstone forma-
tion. Biochem J. 2006;398(3):423–430.
 20. Lavoie B, et al. Hydrophobic bile salts inhibit 
gallbladder smooth muscle function via stimula-
tion of GPBAR1 receptors and activation of KATP 
channels. J Physiol. 2010;588(pt 17):3295–3305.
 21. Li T, et al. The G protein-coupled bile acid recep-
tor, TGR5, stimulates gallbladder filling. Mol 
Endocrinol. 2011;25(6):1066–1071.
 22. Alemi F, et al. The receptor TGR5 mediates the 
prokinetic actions of intestinal bile acids and is 
required for normal defecation in mice. Gastroen-
terology. 2013;144(1):145–154.
 23. Poole DP, et al. Expression and function of the 
bile acid receptor GpBAR1 (TGR5) in the murine 
enteric nervous system. Neurogastroenterol Motil. 
2010;22(7):814–825.
 24. Ward JB, Mroz MS, Keely SJ. The bile acid recep-
tor, TGR5, regulates basal and cholinergic-
induced secretory responses in rat colon. Neuro-
gastroenterol Motil. 2013;25(8):708–711.
 25. Alemi F, et al. The TGR5 receptor mediates bile 
acid-induced itch and analgesia. J Clin Invest. 
2013;123(4):1513–1530.
 26. Thomas C, et al. TGR5-mediated bile acid sens-
ing controls glucose homeostasis. Cell Metab. 
2009;10(3):167–177.
 27. Watanabe M, et al. Bile acids induce 
energy expenditure by promoting intracel-
lular thyroid hormone activation. Nature. 
2006;439(7075):484–489.
 28. Harach T, et al. TGR5 potentiates GLP-1 secre-
tion in response to anionic exchange resins. Sci 
Rep. 2012;2:430.
 29. Potthoff MJ, et al. Colesevelam suppresses hepat-
ic glycogenolysis by TGR5-mediated induction 
of GLP-1 action in DIO mice. Am J Physiol Gastro-
intest Liver Physiol. 2013;304(4):G371–G380.
 30. Kumar DP, et al. Activation of transmembrane 
bile acid receptor TGR5 stimulates insulin secre-
tion in pancreatic beta cells. Biochem Biophys Res 
Commun. 2012;427(3):600–605.
 31. Cipriani S, et al. The bile acid receptor GPBAR-1 
(TGR5) modulates integrity of intestinal barrier 
and immune response to experimental colitis. 
PLoS One. 2011;6(10):e25637.
 32. Haselow K, et al. Bile acids PKA-dependently 
induce a switch of the IL-10/IL-12 ratio and reduce 
proinflammatory capability of human macro-
phages. J Leukoc Biol. 2013;94(6):1253–1264.
 33. Kawamata Y, et al. A G protein-coupled recep-
tor responsive to bile acids. J Biol Chem. 
2003;278(11):9435–9440.
 34. Pols TW, et al. TGR5 activation inhibits athero-
sclerosis by reducing macrophage inflammation 
and lipid loading. Cell Metab. 2011;14(6):747–757.
 35. Wang YD, Chen WD, Yu D, Forman BM, Huang 
W. The G-protein-coupled bile acid receptor, 
Gpbar1 (TGR5), negatively regulates hepatic 
inflammatory response through antagonizing 
nuclear factor kappa light-chain enhancer of 
activated B cells (NF-κB) in mice. Hepatology. 
2011;54(4):1421–1432.
 36. Yoneno K, et al. TGR5 signalling inhibits the 
production of pro-inflammatory cytokines by in 
vitro differentiated inflammatory and intestinal 
macrophages in Crohn’s disease. Immunology. 
2013;139(1):19–29.
 37. Chawla A, Nguyen KD, Goh YP. Macrophage-
mediated inflammation in metabolic disease. 
Nat Rev Immunol. 2011;11(11):738–749.
 38. Chmelar J, Chung KJ, Chavakis T. The role of 
innate immune cells in obese adipose tissue 
inflammation and development of insulin resis-
tance. Thromb Haemost. 2013;109(3):399–406.
 39. Lumeng CN, Saltiel AR. Inflammatory links 
between obesity and metabolic disease. J Clin 
Invest. 2011;121(6):2111–2117.
 40. Han MS, et al. JNK expression by macrophages 
promotes obesity-induced insulin resistance and 
inflammation. Science. 2013;339(6116):218–222.
 41. Wynn TA, Chawla A, Pollard JW. Macrophage 
biology in development, homeostasis and dis-
ease. Nature. 2013;496(7446):445–455.
 42. Clausen BE, Burkhardt C, Reith W, Renkawitz 
R, Forster I. Conditional gene targeting in mac-
rophages and granulocytes using LysMcre mice. 
Transgenic Res. 1999;8(4):265–277.
 43. Pellicciari R, et al. Discovery of 6α-ethyl-23(S)-
methylcholic acid (S-EMCA, INT-777) as a 
potent and selective agonist for the TGR5 recep-
tor, a novel target for diabesity. J Med Chem. 
2009;52(24):7958–7961.
 44. Sato H, et al. Novel potent and selective bile 
acid derivatives as TGR5 agonists: biological 
screening, structure-activity relationships, 
and molecular modeling studies. J Med Chem. 
2008;51(6):1831–1841.
 45. Doherty TM, Kastelein R, Menon S, Andrade 
S, Coffman RL. Modulation of murine 
macrophage function by IL-13. J Immunol. 
1993;151(12):7151–7160.
 46. Doyle AG, et al. Interleukin-13 alters the acti-
vation state of murine macrophages in vitro: 
comparison with interleukin-4 and interferon-
gamma. Eur J Immunol. 1994;24(6):1441–1445.
 47. Stein M, Keshav S, Harris N, Gordon S. Interleu-
kin 4 potently enhances murine macrophage 
mannose receptor activity: a marker of alterna-
tive immunologic macrophage activation. J Exp 
Med. 1992;176(1):287–292.
 48. Mantovani A, Sica A, Sozzani S, Allavena P, Vec-
chi A, Locati M. The chemokine system in diverse 
forms of macrophage activation and polarization. 
Trends Immunol. 2004;25(12):677–686.
 49. Donath MY, Shoelson SE. Type 2 diabetes as 
an inflammatory disease. Nat Rev Immunol. 
2011;11(2):98–107.
 50. Ogawa S, et al. Molecular determinants of cross-
talk between nuclear receptors and toll-like 
receptors. Cell. 2005;122(5):707–721.
 51. Poli V. The role of C/EBP isoforms in the control 
of inflammatory and native immunity functions. 
J Biol Chem. 1998;273(45):29279–29282.
 52. Descombes P, Schibler U. A liver-enriched tran-
scriptional activator protein, LAP, and a tran-
scriptional inhibitory protein, LIP, are translated 
from the same mRNA. Cell. 1991;67(3):569–579.
 53. Arnal-Estape A, et al. HER2 silences tumor 
suppression in breast cancer cells by switching 
expression of C/EBPss isoforms. Cancer Res. 
2010;70(23):9927–9936.
 54. Calkhoven CF, Muller C, Leutz A. Translational 
control of C/EBPα and C/EBPβ isoform expres-
sion. Genes Dev. 2000;14(15):1920–1932.
 55. Dey S, Savant S, Teske BF, Hatzoglou M, Calk-
hoven CF, Wek RC. Transcriptional repression 
of ATF4 gene by CCAAT/enhancer-binding 
protein beta (C/EBPβ) differentially regu-
lates integrated stress response. J Biol Chem. 
2012;287(26):21936–21949.
 56. Bradley MN, Zhou L, Smale ST. C/EBPβ regula-
tion in lipopolysaccharide-stimulated macro-
phages. Mol Cell Biol. 2003;23(14):4841–4858.
 57. Lawrence JC Jr, Abraham RT.  PHAS/4E-BPs as 
regulators of mRNA translation and cell prolif-
eration. Trends Biochem Sci. 1997;22(9):345–349.
 58. Spooner CJ, Guo X, Johnson PF, Schwartz RC. 
Differential roles of C/EBPβ regulatory domains 
in specifying MCP-1 and IL-6 transcription. Mol 
Immunol. 2007;44(6):1384–1392.
 59. Spooner CJ, et al. C/EBPβ serine 64, a phospho-
acceptor site, has a critical role in LPS-induced 
IL-6 and MCP-1 transcription. Cytokine. 
2007;37(2):119–127.
 60. Hu HM, et al. The C/EBP bZIP domain can 
mediate lipopolysaccharide induction of the pro-
inflammatory cytokines interleukin-6 and mono-
cyte chemoattractant protein-1. J Biol Chem. 
2000;275(21):16373–16381.
 61. Cloutier A, Guindi C, Larivee P, Dubois CM, 
Amrani A, McDonald PP. Inflammatory cyto-
kine production by human neutrophils involves 
C/EBP transcription factors. J Immunol. 
2009;182(1):563–571.
 62. Zhang Z, Bryan JL, DeLassus E, Chang LW, Liao 
W, Sandell LJ. CCAAT/enhancer-binding protein 
β and NF-κB mediate high level expression of 
chemokine genes CCL3 and CCL4 by human 
chondrocytes in response to IL-1β. J Biol Chem. 
2010;285(43):33092–33103.
 63. Gregor MF, Hotamisligil GS. Inflammatory 
mechanisms in obesity. Annu Rev Immunol. 
2011;29:415–445.
 64. Glass CK, Olefsky JM. Inflammation and lipid 
Downloaded from http://www.jci.org on January 11, 2016.   http://dx.doi.org/10.1172/JCI76289
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
5 4 3 6 jci.org   Volume 124   Number 12   December 2014
signaling in the etiology of insulin resistance. Cell 
Metab. 2012;15(5):635–645.
 65. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. 
Increased inflammatory properties of adipose 
tissue macrophages recruited during diet-
induced obesity. Diabetes. 2007;56(1):16–23.
 66. Odegaard JI, et al. Macrophage-specific 
PPARgamma controls alternative activa-
tion and improves insulin resistance. Nature. 
2007;447(7148):1116–1120.
 67. Kanda H, et al. MCP-1 contributes to macrophage 
infiltration into adipose tissue, insulin resistance, 
and hepatic steatosis in obesity. J Clin Invest. 
2006;116(6):1494–1505.
 68. Nio Y, et al. Monocyte chemoattractant protein-1 
(MCP-1) deficiency enhances alternatively 
activated M2 macrophages and ameliorates 
insulin resistance and fatty liver in lipoatrophic 
diabetic A-ZIP transgenic mice. Diabetologia. 
2012;55(12):3350–3358.
 69. Tamura Y, et al. Inhibition of CCR2 amelio-
rates insulin resistance and hepatic steatosis 
in db/db mice. Arterioscler Thromb Vasc Biol. 
2008;28(12):2195–2201.
 70. Weisberg SP, et al. CCR2 modulates inflamma-
tory and metabolic effects of high-fat feeding.  
J Clin Invest. 2006;116(1):115–124.
 71. Amano SU, et al. Local proliferation of macrophages 
contributes to obesity-associated adipose tissue 
inflammation. Cell Metab. 2014;19(1):162–171.
 72. Xiong W, Hsieh CC, Kurtz AJ, Rabek JP, Papa-
constantinou J. Regulation of CCAAT/enhancer-
binding protein-β isoform synthesis by alterna-
tive translational initiation at multiple AUG start 
sites. Nucleic Acids Res. 2001;29(14):3087–3098.
 73. Smink JJ, Begay V, Schoenmaker T, Sterneck E, 
de Vries TJ, Leutz A. Transcription factor C/
EBPβ isoform ratio regulates osteoclastogenesis 
through MafB. EMBO J. 2009;28(12):1769–1781.
 74. Hata K, et al. A CCAAT/enhancer binding protein 
beta isoform, liver-enriched inhibitory protein, 
regulates commitment of osteoblasts and adipo-
cytes. Mol Cell Biol. 2005;25(5):1971–1979.
 75. Harrison JR, et al. Col1a1 promoter-targeted 
expression of p20 CCAAT enhancer-binding 
protein beta (C/EBPβ), a truncated C/EBPβ iso-
form, causes osteopenia in transgenic mice. J Biol 
Chem. 2005;280(9):8117–8124.
 76. Zahnow CA, Cardiff RD, Laucirica R, Medina D, 
Rosen JM. A role for CCAAT/enhancer binding 
protein β-liver-enriched inhibitory protein in 
mammary epithelial cell proliferation. Cancer 
Res. 2001;61(1):261–269.
 77. Smink JJ, Tunn PU, Leutz A. Rapamycin inhibits 
osteoclast formation in giant cell tumor of bone 
through the C/EBPβ-MafB axis. J Mol Med (Berl). 
2012;90(1):25–30.
 78. Luedde T, et al. C/EBPβ isoforms LIP and 
LAP modulate progression of the cell cycle 
in the regenerating mouse liver. Hepatology. 
2004;40(2):356–365.
 79. Rahman SM, et al. CCAAT/enhancer-binding 
protein beta (C/EBPβ) expression regulates 
dietary-induced inflammation in macro-
phages and adipose tissue in mice. J Biol Chem. 
2012;287(41):34349–34360.
 80. Wang L, et al. Increased insulin receptor 
substrate-1 and enhanced skeletal muscle 
insulin sensitivity in mice lacking CCAAT/
enhancer-binding protein β. J Biol Chem. 
2000;275(19):14173–14181.
 81. Wethmar K, et al. C/EBPbetaDeltauORF 
mice--a genetic model for uORF-mediated 
translational control in mammals. Genes Dev. 
2010;24(1):15–20.
 82. Dooher JE, Paz-Priel I, Houng S, Baldwin AS Jr, 
Friedman AD. C/EBPα, C/EBPα oncoproteins, 
or C/EBPβ preferentially bind NF-kappaB p50 
compared with p65, focusing therapeutic target-
ing on the C/EBP:p50 interaction. Mol Cancer 
Res. 2011;9(10):1395–1405.
 83. LeClair KP, Blanar MA, Sharp PA. The p50 
subunit of NF-κB associates with the NF-IL6 
transcription factor. Proc Natl Acad Sci U S A. 
1992;89(17):8145–8149.
 84. Matsusaka T, et al. Transcription factors NF-IL6 
and NF-κB synergistically activate transcrip-
tion of the inflammatory cytokines, interleukin 
6 and interleukin 8. Proc Natl Acad Sci U S A. 
1993;90(21):10193–10197.
 85. Stein B, Cogswell PC, Baldwin AS Jr. Functional 
and physical associations between NF-κB and C/
EBP family members: a Rel domain-bZIP inter-
action. Mol Cell Biol. 1993;13(7):3964–3974.
 86. Shaham O, et al. Metabolic profiling of the 
human response to a glucose challenge reveals 
distinct axes of insulin sensitivity. Mol Syst Biol. 
2008;4:214.
 87. Pols TW, Noriega LG, Nomura M, Auwerx J, 
Schoonjans K. The bile acid membrane recep-
tor TGR5: a valuable metabolic target. Dig Dis. 
2011;29(1):37–44.
 88. Pols TW, Noriega LG, Nomura M, Auwerx J, 
Schoonjans K. The bile acid membrane receptor 
TGR5 as an emerging target in metabolism and 
inflammation. J Hepatol. 2011;54(6):1263–1272.
 89. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids 
promote glucagon-like peptide-1 secretion 
through TGR5 in a murine enteroendocrine 
cell line STC-1. Biochem Biophys Res Commun. 
2005;329(1):386–390.
 90. Argmann CA, Champy MF, Auwerx J. Evalua-
tion of energy homeostasis. Curr Protoc Mol Biol. 
2006;Chapter 29:Unit 29B.1.
 91. Matthews DR, Hosker JP, Rudenski AS, Naylor 
BA, Treacher DF, Turner RC. Homeostasis 
model assessment: insulin resistance and β-cell 
function from fasting plasma glucose and 
insulin concentrations in man. Diabetologia. 
1985;28(7):412–419.
 92. Mark M, et al. Histopathology in mouse 
metabolic investigations. Curr Protoc Mol Biol. 
2007;Chapter 29:Unit 29B.4.
Downloaded from http://www.jci.org on January 11, 2016.   http://dx.doi.org/10.1172/JCI76289
